The End of Alzheimer’s Disease: Nudging Strategies to Encourage Mass Participation in Clinical Trials

Characterized by amyloid plaques, tau tangles, and neuronal loss, Alzheimer’s disease (AD) presents a significant public health challenge, with ever-growing prevalence due to an aging global population. By the time cognitive impairment is detected, the disease’s pathology is already extensive and difficult to halt. Despite advances in research and drug development, participation in AD drug trials remains crucial for discovering effective treatments and preventive measures. This article explores how behavioral economics can be employed to raise global awareness about Alzheimer’s, motivate individuals to undergo testing, and encourage involvement in experimental drug trials. By integrating nudging strategies with creative educational approaches, this study aims to increase support for AD research.